Latest market price
26.61
-0.94-3.41%
OverviewShort InterestFilings
NGNEQT25Neurogene Inc.·NASDAQ
26.61-3.41%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-5.51Insider Own38.87%Shs Outstand15.80MPerf Week13.04%
Market Cap420.50MForward P/E—EPS next Y-5.23Insider Trans-0.31%Shs Float12.54MPerf Month3.74%
Enterprise Value200.50MPEG—EPS next Q-1.49Short Float40.63%Perf Quarter-22.67%
Income-111.00MP/S—EPS this Y—Short Ratio19.29Perf Half Y-5.71%
Sales0.00P/B1.94EPS next Y—ROA-45.47%Short Interest5.09MPerf YTD29.17%
Book/sh13.73P/C1.87EPS next 5Y—ROE-45.11%52W High43.66 -39.05%Perf Year-19.70%
Cash/sh14.24P/FCF—EPS past 3/5Y—ROIC-53.72%52W Low15.93 67.04%Perf 3Y95.66%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility13.44% 9.40%Perf 5Y-80.46%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)2.48Perf 10Y-87.59%
Dividend Ex-Date—Quick Ratio10.64Sales Y/Y TTM—Profit Margin0.00%RSI (14)48.38Recom2.14
Dividend Gr. 3/5Y—Current Ratio10.64EPS Q/Q-45.71%SMA204.97%Beta1.68Target Price72.00
Payout0.00%Debt/Eq0.02Sales Q/Q—SMA50-12.74%Rel Volume0.59Prev Close27.55
Employees131LT Debt/Eq0.02EarningsNov 12SMA200-4.49%Avg Volume295.98KPrice26.61
IPO DateMar 07, 2014Option/ShortYes / YesEPS/Sales Surpr.-7.49% —Net Debt/EBITDA—Volume173,616Change-3.41%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-12-26ReiteratedHC Wainwright & Co.Buy$70 → $65
Aug-12-26ReiteratedGuggenheimBuy$69 → $81
Jun-09-26ReiteratedHC Wainwright & Co.Buy$45 → $70
Jun-03-26InitiatedRodman & RenshawBuy$70
Apr-28-26InitiatedGuggenheimBuy$69
Oct-02-25ReiteratedH.C. WainwrightBuy$50 → $45
May-16-25DowngradeBairdOutperform → Neutral
Apr-14-25ReiteratedBMO CapitalOutperform$45 → $16
Mar-25-25ReiteratedRobert W. Baird$46 → $38
Mar-25-25ReiteratedHC Wainwright & Co.Buy$49 → $50
Latest News· Times ET
Oct-27-26
Oct-27-2608:00AM
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndromegurufocus.com
03:32AM
Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated DesignBenzinga
Oct-21-26
Oct-21-2604:15AM
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Surveydefenseworld.net
Oct-20-26
Oct-20-2607:30AM
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual CongressYahoo
Oct-13-26
Oct-13-2609:01AM
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?Yahoo
Oct-12-26
Oct-12-2611:41AM
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?defenseworld.net
Oct-08-26
Oct-08-2605:56AM
JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60Benzinga
Oct-06-26
Oct-06-2609:59AM
Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30Benzinga
Oct-05-26
Oct-05-2604:01PM
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Sep-25-26
Sep-25-2603:17AM
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)defenseworld.net
Sep-11-26
Sep-11-2604:06AM
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNEdefenseworld.net
Sep-08-26
Sep-08-2607:30AM
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conferencebusinesswire.com
Sep-04-26
Sep-04-2604:01PM
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Sep-02-26
Sep-02-2603:52AM
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNEdefenseworld.net
Aug-12-26
Aug-12-2607:53AM
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166Benzinga
Company

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue0010—————
Cost of Goods Sold Incl. D&A19333—————
Gross Profit-19-3-2-3—————
Selling, General and Administrative Excl. Other32252311—————
Research and Development88756144—————
Other Operating Expense-170-4-3—————
Operating Income-122-103-83-56—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)1013719—————
Net Income Before Taxes-111-90-75-36—————
Income Taxes
0000—————
Consolidated Net Income-111-90-75-36—————
Net Income From Continuing Operations-111-90-75-36—————
Net Income-111-90-75-36—————
EPS (Recurring)-5.51-4.24-4.28-2.83—————
EPS (Basic, Before Extraordinaries)-5.51-4.24-4.28-2.83—————
EPS (Diluted)-5.51-4.24-4.28-2.83—————
EBITDA-108-87-72-33—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio——411.48——————
Gross Margin——-200.00——————
Operating Margin——-8,300.00——————
Net Margin——-7,500.00——————
Shares Outstanding23211813—————
Market Capitalization612433411252—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$46.81$38.21$29.61$21.00$12.40● Close Price0.00K93.27K186.53K279.80K373.06KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
McMinn RachelChief Executive OfficerSep 22 '26Option Exercise25.3275619,1421,345,063Oct 02
Cvijic Christine MikailPresident and CFOJul 07 '26Sale36.134,200151,76384,040Jul 07
Cvijic Christine MikailPresident and CFOJul 06 '26Sale36.0260021,61388,240Jul 07
Cvijic Christine MikailPresident and CFOJul 02 '26Sale34.824,061141,41688,840Jul 02
Cvijic Christine MikailPresident and CFOJul 01 '26Sale34.0673925,17092,901Jul 02
Cvijic Christine MikailPresident and CFOMay 06 '26Sale31.259,600300,04393,640May 08
Cvijic Christine MikailPresident and CFOMar 26 '26Sale21.622,55855,316103,240Mar 30
McMinn RachelChief Executive OfficerMar 26 '26Sale22.073,35273,9951,344,307Mar 30
Jordan JulieChief Medical OfficerMar 26 '26Sale21.8982818,12812,472Mar 30
Cobb StuartChief Scientific OfficerMar 13 '26Sale20.816,797141,44630,497Mar 17
Cvijic Christine MikailPresident and CFOMar 13 '26Sale20.814,04584,176105,798Mar 17
Cvijic Christine MikailPresident and CFOFeb 27 '26Sale25.114,800120,526109,843Mar 03
Cobb StuartChief Scientific OfficerMay 14 '25Sale15.156,797103,00320,794May 15
Cvijic Christine MikailPresident and CFOMar 13 '25Sale16.944,50176,24772,343Mar 17
Samsara BioCapital GP, LLC10% OwnerNov 26 '24Buy25.8348,7701,259,6231,717,127Nov 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.